BrainVectis

BrainVectis

BrainVectis

BrainVectis's aim is to treat neurodegenerative diseases by restoring brain cholesterol metabolism our site
Type
B2b
Founded
2015
Raised
$1.2M
Follow us
Alexa global traffic share
Twitter followers
Acquired by
Asklepios BioPharmaceutical
1
Latest funding
€1,000,000
Undisclosed
Location
Headquarters
Acquisition
FinSMEs

Asklepios BioPharmaceutical Acquires BrainVectis

€1,000,000 Venture capital (Series A)
FinSMEs , pharmiweb

BrainVectis Raises €1M in Funding